{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:01:25Z","timestamp":1787032885485,"version":"build-2736575974"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,16]]},"DOI":"10.7759\/cureus.60434","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T11:21:26Z","timestamp":1715858486000},"source":"Crossref","is-referenced-by-count":5,"title":["A Narrative Review of Chondrocalcinosis: Clinical Presentation, Diagnosis, and Therapies"],"prefix":"10.7759","author":[{"given":"Soo Yeon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Afroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-56-5-738","article-title":"The significance of calcium phosphate crystals in the synovial fl uid of arthritic patients: the \u201cpseudogout syndrome\u201d. II. Identification of crystals","volume":"56","author":"Kohn N","year":"1962","unstructured":"Kohn N, Hughes R, McCarty D Jr, et al.. The significance of calcium phosphate crystals in the synovial fl uid of arthritic patients: the \u201cpseudogout syndrome\u201d. II. Identification of crystals. Ann Intern Med. 1962, 56:738-45.","journal-title":"Ann Intern Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.139105","article-title":"European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis","volume":"70","author":"Zhang W","year":"2011","unstructured":"Zhang W, Doherty M, Bardin T, et al.. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis. 2011, 70:563-70. 10.1136\/ard.2010.139105","journal-title":"Ann Rheum Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1511117","article-title":"Calcium pyrophosphate deposition disease","volume":"374","author":"Rosenthal AK","year":"2016","unstructured":"Rosenthal AK, Ryan LM. Calcium pyrophosphate deposition disease. N Engl J Med. 2016, 374:2575-84. 10.1056\/NEJMra1511117","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/art.42619","article-title":"The 2023 ACR\/EULAR classification criteria for calcium pyrophosphate deposition disease","volume":"75","author":"Abhishek A","year":"2023","unstructured":"Abhishek A, Tedeschi SK, Pascart T, et al.. The 2023 ACR\/EULAR classification criteria for calcium pyrophosphate deposition disease. Arthritis Rheumatol. 2023, 75:1703-13. 10.1002\/art.42619","journal-title":"Arthritis Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23160","article-title":"Calcium pyrophosphate deposition disease and associated medical co-morbidities: a national cross-sectional study of US veterans","volume":"69","author":"Balderrama CK","year":"2017","unstructured":"Balderrama CK, Rosenthal AK, Lans D, Singh JA, Bartels CM. Calcium pyrophosphate deposition disease and associated medical co-morbidities: a national cross-sectional study of US veterans. Arthritis Care Res (Hoboken). 2017, 69:1400-6. 10.1002\/acr.23160","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-011-0230-6","article-title":"Genetics and mechanisms of crystal deposition in calcium pyrophosphate deposition disease.","volume":"14","author":"Tsui F","year":"2012","unstructured":"Tsui F. Genetics and mechanisms of crystal deposition in calcium pyrophosphate deposition disease.. Curr Rheumatol Rep. 2012, 14:155-60.","journal-title":"Curr Rheumatol Rep"},{"key":"ref7","article-title":"EULAR recommendations for calcium pyrophosphate deposition. Part II: Management","volume":"70","author":"Zhang W","year":"2011","unstructured":"Zhang W, Doherty M, Pascual E, et al.. EULAR recommendations for calcium pyrophosphate deposition. Part II: Management. Annals of the Rheumatic Diseases. 2011, 70:571-575.","journal-title":"Annals of the Rheumatic Diseases"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2021.101722","article-title":"The role of calcium crystals and their effect on osteoarthritis pathogenesis","volume":"35","author":"St\u00fccker S","year":"2021","unstructured":"St\u00fccker S, Bollmann M, Garbers C, Bertrand J. The role of calcium crystals and their effect on osteoarthritis pathogenesis. Best Pract Res Clin Rheumatol. 2021, 35:101722. 10.1016\/j.berh.2021.101722","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref9","article-title":"Vesicles associated with calcification in the matrix of epiphyseal cartilage","volume":"41","author":"Clarke Anderson H","year":"1969","unstructured":"Clarke Anderson H. Vesicles associated with calcification in the matrix of epiphyseal cartilage. J Cell Biol. 1969, 41:59-72.","journal-title":"J Cell Biol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1039\/c7md00015d","article-title":"Nucleotide pyrophosphatase\/phosphodiesterase 1 (NPP1) and its inhibitors","volume":"8","author":"Lee SY","year":"2017","unstructured":"Lee SY, M\u00fcller CE. Nucleotide pyrophosphatase\/phosphodiesterase 1 (NPP1) and its inhibitors. Medchemcomm. 2017, 8:823-40. 10.1039\/c7md00015d","journal-title":"Medchemcomm"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2021.101718","article-title":"Pathogenesis of calcium pyrophosphate deposition disease","volume":"35","author":"Williams C","year":"2021","unstructured":"Williams C, Rosenthal A. Pathogenesis of calcium pyrophosphate deposition disease. Best Pract Res Clin Rheumatol. 2021, 35:101718-10.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref12","article-title":"Hypophosphatasia - pathophysiology and treatment","volume":"8","author":"Mill\u00e1n JL","year":"2012","unstructured":"Mill\u00e1n JL, Plotkin H. Hypophosphatasia - pathophysiology and treatment. Actual osteol. 2012, 8:164-82.","journal-title":"Actual osteol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-016-0574-z","article-title":"The Role of ANK in calcium pyrophosphate deposition disease","volume":"18","author":"Mitton-Fitzgerald E","year":"2016","unstructured":"Mitton-Fitzgerald E, Gohr CM, Bettendorf B, Rosenthal AK. The Role of ANK in calcium pyrophosphate deposition disease. Curr Rheumatol Rep. 2016, 18:25. 10.1007\/s11926-016-0574-z","journal-title":"Curr Rheumatol Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-007-0037-7","article-title":"Genetic factors in the pathogenesis of CPPD crystal deposition disease","volume":"9","author":"Couto AR","year":"2007","unstructured":"Couto AR, Brown MA. Genetic factors in the pathogenesis of CPPD crystal deposition disease. Curr Rheumatol Rep. 2007, 9:231-6. 10.1007\/s11926-007-0037-7","journal-title":"Curr Rheumatol Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/ar4337","article-title":"The progressive ankylosis gene product ANK regulates extracellular ATP levels in primary articular chondrocytes","volume":"15","author":"Rosenthal AK","year":"2013","unstructured":"Rosenthal AK, Gohr CM, Mitton-Fitzgerald E, Lutz MK, Dubyak GR, Ryan LM. The progressive ankylosis gene product ANK regulates extracellular ATP levels in primary articular chondrocytes. Arthritis Res Ther. 2013, 15:R154. 10.1186\/ar4337","journal-title":"Arthritis Res Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2010.03.005","article-title":"Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome","volume":"21","author":"Mitroulis I","year":"2010","unstructured":"Mitroulis I, Skendros P, Ritis K. Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome. Eur J Intern Med. 2010, 21:157-63. 10.1016\/j.ejim.2010.03.005","journal-title":"Eur J Intern Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/ar4043","article-title":"Chondrocalcinosis is common in the absence of knee involvement","volume":"14","author":"Abhishek A","year":"2012","unstructured":"Abhishek A, Doherty S, Maciewicz R, Muir K, Zhang W, Doherty M. Chondrocalcinosis is common in the absence of knee involvement. Arthritis Res Ther. 2012, 14:R205. 10.1186\/ar4043","journal-title":"Arthritis Res Ther"},{"key":"ref18","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2017-212542","article-title":"Identification of calcium pyrophosphate deposition disease (CPPD) by ultrasound: reliability of the OMERACT definitions in an extended set of joints\u2014an international multiobserver study by the OMERACT Calcium Pyrophosphate Deposition Disease Ultrasound Subtask Force","author":"Filippou","year":"2018","unstructured":"Filippou, Georgios. Identification of calcium pyrophosphate deposition disease (CPPD) by ultrasound: reliability of the OMERACT definitions in an extended set of joints\u2014an international multiobserver study by the OMERACT Calcium Pyrophosphate Deposition Disease Ultrasound Subtask Force. Ann Rheum Dis. 2018, 1194-9.","journal-title":"Ann Rheum Dis"},{"key":"ref19","article-title":"Diagnosis and treatment of calcium pyrophosphate deposition (CPPD) disease: a review","author":"Cowley S","year":"2023","unstructured":"Cowley S, McCarthy G. Diagnosis and treatment of calcium pyrophosphate deposition (CPPD) disease: a review. Open Access Rheumatol: Res Rev. 2023, 33-41.","journal-title":"Open Access Rheumatol: Res Rev"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-23488-0_37","article-title":"CPPD and other microcrystalline disorders","author":"Rosenthal A","year":"2023","unstructured":"Rosenthal A. CPPD and other microcrystalline disorders. A Clinician's Pearls & Myths in Rheumatology. Springer International Publishing, Cham; 2023. 531-43. 10.1007\/978-3-031-23488-0_37"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24898","article-title":"Imaging features of calcium pyrophosphate deposition disease: consensus definitions from an international multidisciplinary working group","volume":"75","author":"Tedeschi SK","year":"2023","unstructured":"Tedeschi SK, Becce F, Pascart T, et al.. Imaging features of calcium pyrophosphate deposition disease: consensus definitions from an international multidisciplinary working group. Arthritis Care Res (Hoboken). 2023, 75:825-34. 10.1002\/acr.24898","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2179-5","article-title":"Crowned dens syndrome: a rare cause of acute neck pain","volume":"32","author":"Uh M","year":"2013","unstructured":"Uh M, Dewar C, Spouge D, Blocka K. Crowned dens syndrome: a rare cause of acute neck pain. Clin Rheumatol. 2013, 32:711-4. 10.1007\/s10067-013-2179-5","journal-title":"Clin Rheumatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1177\/1071100714560399","article-title":"Destructive pseudo-neuroarthropathy associated with calcium pyrophosphate deposition","volume":"36","author":"Lomax A","year":"2015","unstructured":"Lomax A, Ferrero A, Cullen N, Goldberg A, Singh D. Destructive pseudo-neuroarthropathy associated with calcium pyrophosphate deposition. Foot Ankle Int. 2015, 36:383-90. 10.1177\/1071100714560399","journal-title":"Foot Ankle Int"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/RLI.0000000000000756","article-title":"Dual-energy computed tomography for detection and characterization of monosodium urate, calcium pyrophosphate, and hydroxyapatite: a phantom study on diagnostic performance","volume":"56","author":"D\u00f8ssing A","year":"2021","unstructured":"D\u00f8ssing A, M\u00fcller FC, Becce F, Stamp L, Bliddal H, Boesen M. Dual-energy computed tomography for detection and characterization of monosodium urate, calcium pyrophosphate, and hydroxyapatite: a phantom study on diagnostic performance. Invest Radiol. 2021, 56:417-24. 10.1097\/RLI.0000000000000756","journal-title":"Invest Radiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4081\/reumatismo.2023.1583","article-title":"Ultrasound imaging in crystal arthropathies: a pictorial review","volume":"75","author":"Tamborrini G","year":"2023","unstructured":"Tamborrini G, H\u00fcgle T, Ricci V, Filippou G. Ultrasound imaging in crystal arthropathies: a pictorial review. Reumatismo. 2023, 75:10.4081\/reumatismo.2023.1583","journal-title":"Reumatismo"},{"key":"ref26","article-title":"Update on calcium pyrophosphate deposition","volume":"34","author":"Abhishek A","year":"2016","unstructured":"Abhishek A, Doherty M. Update on calcium pyrophosphate deposition. Clin Exp Rheumatol. 2016, 34:32-8.","journal-title":"Clin Exp Rheumatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05949-4","article-title":"The role of dual energy computed tomography in the differentiation of acute gout flares and acute calcium pyrophosphate crystal arthritis","volume":"41","author":"Kravchenko D","year":"2022","unstructured":"Kravchenko D, Karakostas P, Kuetting D, Meyer C, Brossart P, Behning C, Sch\u00e4fer VS. The role of dual energy computed tomography in the differentiation of acute gout flares and acute calcium pyrophosphate crystal arthritis. Clin Rheumatol. 2022, 41:223-33. 10.1007\/s10067-021-05949-4","journal-title":"Clin Rheumatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20936060","article-title":"Dual-energy computed-tomography-based discrimination between basic calcium phosphate and calcium pyrophosphate crystal deposition in vivo","volume":"12","author":"Pascart T","year":"2020","unstructured":"Pascart T, Falgayrac G, Norberciak L, et al.. Dual-energy computed-tomography-based discrimination between basic calcium phosphate and calcium pyrophosphate crystal deposition in vivo. Ther Adv Musculoskelet Dis. 2020, 12:1759720X20936060. 10.1177\/1759720X20936060","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref29","article-title":"EULAR recommendations for calcium pyrophosphate deposition. Part II: management","author":"Zhang W","year":"2011","unstructured":"Zhang W. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis. 2011, 571-5.","journal-title":"Ann Rheum Dis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cobme.2018.08.007","article-title":"Temporal pattern of electrical stimulation is a new dimension of therapeutic innovation","volume":"8","author":"Grill WM","year":"2018","unstructured":"Grill WM. Temporal pattern of electrical stimulation is a new dimension of therapeutic innovation. Curr Opin Biomed Eng. 2018, 8:1-6. 10.1016\/j.cobme.2018.08.007","journal-title":"Curr Opin Biomed Eng"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1327715","article-title":"Recent advances in the therapeutic management of calcium pyrophosphate deposition disease","volume":"11","author":"Voulgari PV","year":"2024","unstructured":"Voulgari PV, Venetsanopoulou AI, Drosos AA. Recent advances in the therapeutic management of calcium pyrophosphate deposition disease. Front Med (Lausanne). 2024, 11:1327715. 10.3389\/fmed.2024.1327715","journal-title":"Front Med (Lausanne)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.5694\/mja14.00846","article-title":"Colchicine--a short history of an ancient drug","volume":"201","author":"Nerlekar N","year":"2014","unstructured":"Nerlekar N, Beale A, Harper RW. Colchicine--a short history of an ancient drug. Med J Aust. 2014, 201:687-8. 10.5694\/mja14.00846","journal-title":"Med J Aust"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.10.005","article-title":"Management of calcium pyrophosphate crystal deposition disease: a systematic review","volume":"51","author":"Parperis K","year":"2021","unstructured":"Parperis K, Papachristodoulou E, Kakoullis L, Rosenthal AK. Management of calcium pyrophosphate crystal deposition disease: a systematic review. Semin Arthritis Rheum. 2021, 51:84-94. 10.1016\/j.semarthrit.2020.10.005","journal-title":"Semin Arthritis Rheum"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine--update on mechanisms of action and therapeutic uses","volume":"45","author":"Leung YY","year":"2015","unstructured":"Leung YY, Yao Hui LL, Kraus VB. Colchicine--update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015, 45:341-50. 10.1016\/j.semarthrit.2015.06.013","journal-title":"Semin Arthritis Rheum"},{"key":"ref35","doi-asserted-by":"crossref","DOI":"10.1002\/art.1780251226","article-title":"Colchicine and pseudogout","author":"Gonz\u00e1lez T","year":"1982","unstructured":"Gonz\u00e1lez T, Gantes M. Colchicine and pseudogout. Arthritis Rheum. 1982, 1509-10.","journal-title":"Arthritis Rheum"},{"key":"ref36","article-title":"Colchicine prophylaxis in pseudogout","volume":"13","author":"Alvarellos A","year":"1986","unstructured":"Alvarellos A, Spilberg I. Colchicine prophylaxis in pseudogout. J Rheumatol. 1986, 13:804-5.","journal-title":"J Rheumatol"},{"key":"ref37","doi-asserted-by":"crossref","DOI":"10.1001\/jama.1973.03230010020004","article-title":"Pseudogout syndrome in hospital patients","volume":"226","author":"O'Duffy JD","year":"1973","unstructured":"O'Duffy JD. Pseudogout syndrome in hospital patients. JAMA. 1973, 226:42-4.","journal-title":"JAMA"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.25259\/JNRP-2022-6-31","article-title":"Cost-effectiveness of adrenocorticotropic hormone injection and oral prednisolone in patients with West syndrome: A comparative analysis","volume":"14","author":"Sharawat IK","year":"2023","unstructured":"Sharawat IK, Panda PK, Ramachandran A, Bhadoria AS. Cost-effectiveness of adrenocorticotropic hormone injection and oral prednisolone in patients with West syndrome: A comparative analysis. J Neurosci Rural Pract. 2023, 14:103-10. 10.25259\/JNRP-2022-6-31","journal-title":"J Neurosci Rural Pract"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06573-0","article-title":"A single-centre retrospective case series of Anakinra for incident calcium pyrophosphate deposition disease","volume":"42","author":"Lian A","year":"2023","unstructured":"Lian A, Shandilya A, Riordan J. A single-centre retrospective case series of Anakinra for incident calcium pyrophosphate deposition disease. Clin Rheumatol. 2023, 42:1833-7. 10.1007\/s10067-023-06573-0","journal-title":"Clin Rheumatol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2020.105088","article-title":"Anakinra compared to prednisone in the treatment of acute CPPD crystal arthritis: A randomized controlled double-blinded pilot study","volume":"88","author":"Dumusc A","year":"2021","unstructured":"Dumusc A, Pazar Maldonado B, Benaim C, Zufferey P, Aubry-Rozier B, So A. Anakinra compared to prednisone in the treatment of acute CPPD crystal arthritis: A randomized controlled double-blinded pilot study. Joint Bone Spine. 2021, 88:105088. 10.1016\/j.jbspin.2020.105088","journal-title":"Joint Bone Spine"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180393","article-title":"Utility of anakinra in acute crystalline diseases: a retrospective study comparing a university hospital with a Veterans Affairs Medical Center","volume":"46","author":"Desmarais J","year":"2019","unstructured":"Desmarais J, Chu CQ. Utility of anakinra in acute crystalline diseases: a retrospective study comparing a university hospital with a Veterans Affairs Medical Center. J Rheumatol. 2019, 46:748-50. 10.3899\/jrheum.180393","journal-title":"J Rheumatol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2009.10.011","article-title":"Anti-IL-1 molecules: new comers and new indications","volume":"77","author":"Molt\u00f3 A","year":"2010","unstructured":"Molt\u00f3 A, Oliv\u00e9 A. Anti-IL-1 molecules: new comers and new indications. Joint Bone Spine. 2010, 77:102-7. 10.1016\/j.jbspin.2009.10.011","journal-title":"Joint Bone Spine"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2012.07.018","article-title":"Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: a report of 16 cases and review of the literature","volume":"80","author":"Ottaviani S","year":"2013","unstructured":"Ottaviani S, Brunier L, Sibilia J, et al.. Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: a report of 16 cases and review of the literature. Joint Bone Spine. 2013, 80:178-82. 10.1016\/j.jbspin.2012.07.018","journal-title":"Joint Bone Spine"},{"key":"ref44","doi-asserted-by":"crossref","DOI":"10.1002\/art.27600","article-title":"Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study","author":"So A","year":"2010","unstructured":"So A, De Meulemeester M, Pikhlak A, et al.. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 2010, 3064-76.","journal-title":"Arthritis Rheum"},{"key":"ref45","article-title":"Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial","volume":"280","author":"Viola K","year":"2020","unstructured":"Viola K. Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial. Lancet Rheumatology. 2020, 280:e270-e280.","journal-title":"Lancet Rheumatology"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1258\/jrsm.2012.12k013","article-title":"Observations of unprecedented remissions following novel treatment for acute leukemia in children in 1948","volume":"105","author":"Spain PD","year":"2012","unstructured":"Spain PD, Kadan-Lottick N. Observations of unprecedented remissions following novel treatment for acute leukemia in children in 1948. J R Soc Med. 2012, 105:177-81. 10.1258\/jrsm.2012.12k013","journal-title":"J R Soc Med"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e318262280b","article-title":"Methotrexate is an option for patients with refractory calcium pyrophosphate crystal arthritis","volume":"18","author":"Mariano A","year":"2012","unstructured":"Mariano A, Sivera F, Pascual E. Methotrexate is an option for patients with refractory calcium pyrophosphate crystal arthritis. J Clin Rheumatol. 2012, 18:234-6. 10.1097\/RHU.0b013e318262280b","journal-title":"J Clin Rheumatol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.2147\/OARRR.S39039","article-title":"Calcium pyrophosphate crystal deposition disease: diagnosis and treatment","volume":"6","author":"Rosales-Alexander JL","year":"2014","unstructured":"Rosales-Alexander JL, Balsalobre Aznar J, Magro-Checa C. Calcium pyrophosphate crystal deposition disease: diagnosis and treatment. Open Access Rheumatol. 2014, 6:39-47. 10.2147\/OARRR.S39039","journal-title":"Open Access Rheumatol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-014-0458-4","article-title":"Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial","volume":"16","author":"Finckh A","year":"2014","unstructured":"Finckh A, Mc Carthy GM, Madigan A, et al.. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial. Arthritis Res Ther. 2014, 16:458. 10.1186\/s13075-014-0458-4","journal-title":"Arthritis Res Ther"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.3840","article-title":"Updated treatment for calcium pyrophosphate deposition disease: an insight","volume":"11","author":"Iqbal SM","year":"2019","unstructured":"Iqbal SM, Qadir S, Aslam HM, Qadir MA. Updated treatment for calcium pyrophosphate deposition disease: an insight. Cureus. 2019, 11:e3840. 10.7759\/cureus.3840","journal-title":"Cureus"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.139048","article-title":"Sodium overload and water influx activate the NALP3 inflammasome","volume":"286","author":"Schorn C","year":"2011","unstructured":"Schorn C, Frey B, Lauber K, et al.. Sodium overload and water influx activate the NALP3 inflammasome. J Biol Chem. 2011, 286:35-41. 10.1074\/jbc.M110.139048","journal-title":"J Biol Chem"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1002\/art.22389","article-title":"Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis","volume":"56","author":"Chollet-Janin A","year":"2007","unstructured":"Chollet-Janin A, Finckh A, Dudler J, Guerne PA. Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum. 2007, 56:688-92. 10.1002\/art.22389","journal-title":"Arthritis Rheum"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/239142-a-narrative-review-of-chondrocalcinosis-clinical-presentation-diagnosis-and-therapies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T11:21:36Z","timestamp":1715858496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/239142-a-narrative-review-of-chondrocalcinosis-clinical-presentation-diagnosis-and-therapies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":52,"URL":"https:\/\/doi.org\/10.7759\/cureus.60434","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,16]]}}}